Biomerica Receives First Commercial Order for Hp Detect
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 18 2026
0mins
Should l Buy BMRA?
Biomerica announced it has received its first commercial order for Hp Detect, its Helicobacter pylori diagnostic stool antigen test, from one of the largest clinical laboratory chains operating across Europe. The initial order is for the United Kingdom market, where Hp Detect received registration from the UK Medicines and Healthcare products Regulatory Agency, or MHRA in February. This commercial order represents a significant step in Biomerica's commercialization of Hp Detect throughout Europe. The customer's position as one of the leading clinical laboratory networks in Europe provides Biomerica with a high-profile account that the Company believes will support future distribution discussions across the broader EU market. H. pylori is one of the most prevalent bacterial infections worldwide, estimated to infect 45% of the population across Europe's five largest countries. It is the strongest known risk factor for gastric cancer and is designated by the WHO as a Class 1 carcinogen. The WHO also lists H. pylori among the 16 antibiotic-resistant bacteria posing the greatest threat to human health, increasing the urgency for accurate, timely diagnostics to guide appropriate treatment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BMRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BMRA
About BMRA
Biomerica, Inc. is a biomedical technology company. The Company develops, patents, manufactures and markets advanced diagnostic and therapeutic products. Its diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients in the diagnosis of various diseases, food intolerances, and other medical complications. The Company’s diagnostic test kits can also be used to measure or detect the presence and levels of specific bacteria, hormones, antibodies, antigens and other substances, which may exist in the human body in small concentrations. Its range of medical diagnostic products is sold in two markets: clinical laboratories and point-of-care settings. The Company’s diagnostic-guided therapy (DGT) product, developed on the inFoods technology platform, is designed to aid in the management of gastrointestinal conditions such as irritable bowel syndrome (IBS) and other inflammatory diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biomerica Secures First Commercial Order for Hp Detect Test
- First Commercial Order: Biomerica announced it has secured its first commercial order for the Hp Detect H. pylori test from a major European lab chain, specifically targeting the UK market, marking a significant step in the company's expansion into European commercialization.
- Regulatory Approval Context: This order follows the MHRA clearance obtained in February 2026, demonstrating the company's capability to meet stringent regulatory requirements, thereby enhancing its competitive position in the European market.
- Market Expansion Potential: The order is expected to support further distribution partnerships in the U.S. and EU markets, driving the company's market penetration and sales growth on a global scale.
- Stock Price Reaction: Following this announcement, Biomerica's shares rose by 4.00%, reflecting investor optimism regarding the company's future growth potential.
See More
Biomerica (BMRA) Reports Q2 Loss of $1.32 Million, Revenue Down 26.2%
- Widening Losses: Biomerica reported a net loss of $1.32 million in Q2, a 39.5% increase from last year's loss of $0.95 million, indicating greater pressure on the company's profitability.
- Revenue Decline: The company's revenue fell to $1.21 million, down 26.2% from $1.64 million last year, reflecting weak market demand and sales challenges that could impact future liquidity.
- Performance Comparison: The loss per share widened from $0.09 to $0.12 compared to the same period last year, suggesting that efforts to control costs and boost revenue have not yielded expected results.
- Market Outlook: With both revenue and profitability declining, Biomerica may need to reassess its market strategy to navigate the current economic environment and competitive pressures in the industry.
See More
Biomerica (BMRA) Reports Q2 Net Loss of $1.32M, Revenue Down 26.2% YoY
- Financial Performance Decline: Biomerica reported a Q2 net loss of $1.32 million, which is a 39% increase from a $0.95 million loss in the same quarter last year, indicating greater pressure on the company's profitability.
- Significant Revenue Drop: The company's revenue fell to $1.21 million, down 26.2% year-over-year, reflecting weak market demand and insufficient sales strategies, which could impact future liquidity.
- Investor Attention: As financial performance worsens, investor interest in Biomerica is likely to increase, potentially leading to heightened stock price volatility and affecting the company's ability to raise capital in the market.
- Uncertain Future Outlook: Given the current financial situation, Biomerica needs to reassess its business strategy to address market challenges and restore growth potential.
See More
Biomerica (BMRA) Launches AI-Driven IBS Test Amid 4% Revenue Decline
- Collaborative Promotion: Biomerica entered a marketing services agreement with Henry Schein to support the commercialization of its inFoods®IBS test in the U.S., aiming to enhance awareness among healthcare providers and drive broader adoption in clinical practice.
- AI Tool Launch: The introduction of the inFoods®IBS Trigger Food Navigator, an AI-driven digital companion tool designed to improve patient dietary compliance and treatment success, helps patients identify 2 to 4 specific foods that trigger IBS symptoms, providing a personalized dietary plan.
- Medicare Payment Rate Established: The CMS set a national Medicare payment rate of $300 for the inFoods®IBS test, effective January 1, 2026, which will expand patient access to the product through the Medicare system, enhancing market penetration.
- International Expansion Authorization: The Egyptian Drug Authority authorized Biomerica's complete screening test portfolio, further expanding access to the company's rapid diagnostic solutions in Egypt and supporting the ongoing international expansion of Biomerica's diagnostic products.
See More
Biomerica Announces $300 Medicare Payment for inFoods IBS Test
- Medicare Payment Established: CMS has set a national Medicare payment rate of $300 for Biomerica's inFoods IBS test, effective January 1, 2026, which is expected to significantly enhance patient access and lay a foundation for the company's future commercial growth.
- Substantial Market Potential: With approximately 30 million IBS patients in the U.S., the inFoods IBS test addresses this unmet medical need through a personalized diagnostic approach, likely driving the company's market share in the rapidly growing gastrointestinal disease sector.
- Strong Clinical Validation: In a multicenter randomized controlled trial, 59.6% of patients who eliminated trigger foods identified by the inFoods IBS test achieved abdominal pain reduction, significantly higher than the 42.2% in the control group, providing robust clinical support for product marketing.
- Optimized Commercial Strategy: Biomerica plans to use the CMS payment rate as a benchmark for negotiations with private insurers while expanding collaborations with gastroenterology practices to further enhance market penetration.
See More
Biomerica Secures EDA Authorization for Multiple Cancer Screening Tests
- Market Access Breakthrough: Biomerica has received authorization from the Egyptian Drug Authority to promote its rapid screening tests, which is expected to significantly enhance early detection rates for cancers and chronic diseases in Egypt, addressing the growing health needs of the population.
- Diverse Product Portfolio: The authorization covers multiple products including the EZ Detect™ Colon Disease Test, Aware® Breast Self Exam, and Fortel Prostate PSA Test, designed to support early disease identification through convenient home testing, thereby reducing healthcare costs.
- Addressing Public Health Challenges: With colorectal cancer incidence in Egypt at approximately 5-10 cases per 100,000 people annually, Biomerica's testing tools will aid in identifying high-risk populations, facilitating a shift in national public health policies towards early detection and improving patient outcomes.
- Strategic Expansion Plans: This authorization not only strengthens Biomerica's market position in the Middle East and North Africa but also provides opportunities for large-scale screening initiatives in underserved areas, further advancing global preventive healthcare trends.
See More
Biomerica Secures First Commercial Order for Hp Detect Test
- First Commercial Order: Biomerica announced it has secured its first commercial order for the Hp Detect H. pylori test from a major European lab chain, specifically targeting the UK market, marking a significant step in the company's expansion into European commercialization.
- Regulatory Approval Context: This order follows the MHRA clearance obtained in February 2026, demonstrating the company's capability to meet stringent regulatory requirements, thereby enhancing its competitive position in the European market.
- Market Expansion Potential: The order is expected to support further distribution partnerships in the U.S. and EU markets, driving the company's market penetration and sales growth on a global scale.
- Stock Price Reaction: Following this announcement, Biomerica's shares rose by 4.00%, reflecting investor optimism regarding the company's future growth potential.
See More
Biomerica (BMRA) Reports Q2 Loss of $1.32 Million, Revenue Down 26.2%
- Widening Losses: Biomerica reported a net loss of $1.32 million in Q2, a 39.5% increase from last year's loss of $0.95 million, indicating greater pressure on the company's profitability.
- Revenue Decline: The company's revenue fell to $1.21 million, down 26.2% from $1.64 million last year, reflecting weak market demand and sales challenges that could impact future liquidity.
- Performance Comparison: The loss per share widened from $0.09 to $0.12 compared to the same period last year, suggesting that efforts to control costs and boost revenue have not yielded expected results.
- Market Outlook: With both revenue and profitability declining, Biomerica may need to reassess its market strategy to navigate the current economic environment and competitive pressures in the industry.
See More
Biomerica (BMRA) Reports Q2 Net Loss of $1.32M, Revenue Down 26.2% YoY
- Financial Performance Decline: Biomerica reported a Q2 net loss of $1.32 million, which is a 39% increase from a $0.95 million loss in the same quarter last year, indicating greater pressure on the company's profitability.
- Significant Revenue Drop: The company's revenue fell to $1.21 million, down 26.2% year-over-year, reflecting weak market demand and insufficient sales strategies, which could impact future liquidity.
- Investor Attention: As financial performance worsens, investor interest in Biomerica is likely to increase, potentially leading to heightened stock price volatility and affecting the company's ability to raise capital in the market.
- Uncertain Future Outlook: Given the current financial situation, Biomerica needs to reassess its business strategy to address market challenges and restore growth potential.
See More
Biomerica (BMRA) Launches AI-Driven IBS Test Amid 4% Revenue Decline
- Collaborative Promotion: Biomerica entered a marketing services agreement with Henry Schein to support the commercialization of its inFoods®IBS test in the U.S., aiming to enhance awareness among healthcare providers and drive broader adoption in clinical practice.
- AI Tool Launch: The introduction of the inFoods®IBS Trigger Food Navigator, an AI-driven digital companion tool designed to improve patient dietary compliance and treatment success, helps patients identify 2 to 4 specific foods that trigger IBS symptoms, providing a personalized dietary plan.
- Medicare Payment Rate Established: The CMS set a national Medicare payment rate of $300 for the inFoods®IBS test, effective January 1, 2026, which will expand patient access to the product through the Medicare system, enhancing market penetration.
- International Expansion Authorization: The Egyptian Drug Authority authorized Biomerica's complete screening test portfolio, further expanding access to the company's rapid diagnostic solutions in Egypt and supporting the ongoing international expansion of Biomerica's diagnostic products.
See More
Biomerica Announces $300 Medicare Payment for inFoods IBS Test
- Medicare Payment Established: CMS has set a national Medicare payment rate of $300 for Biomerica's inFoods IBS test, effective January 1, 2026, which is expected to significantly enhance patient access and lay a foundation for the company's future commercial growth.
- Substantial Market Potential: With approximately 30 million IBS patients in the U.S., the inFoods IBS test addresses this unmet medical need through a personalized diagnostic approach, likely driving the company's market share in the rapidly growing gastrointestinal disease sector.
- Strong Clinical Validation: In a multicenter randomized controlled trial, 59.6% of patients who eliminated trigger foods identified by the inFoods IBS test achieved abdominal pain reduction, significantly higher than the 42.2% in the control group, providing robust clinical support for product marketing.
- Optimized Commercial Strategy: Biomerica plans to use the CMS payment rate as a benchmark for negotiations with private insurers while expanding collaborations with gastroenterology practices to further enhance market penetration.
See More
Biomerica Secures EDA Authorization for Multiple Cancer Screening Tests
- Market Access Breakthrough: Biomerica has received authorization from the Egyptian Drug Authority to promote its rapid screening tests, which is expected to significantly enhance early detection rates for cancers and chronic diseases in Egypt, addressing the growing health needs of the population.
- Diverse Product Portfolio: The authorization covers multiple products including the EZ Detect™ Colon Disease Test, Aware® Breast Self Exam, and Fortel Prostate PSA Test, designed to support early disease identification through convenient home testing, thereby reducing healthcare costs.
- Addressing Public Health Challenges: With colorectal cancer incidence in Egypt at approximately 5-10 cases per 100,000 people annually, Biomerica's testing tools will aid in identifying high-risk populations, facilitating a shift in national public health policies towards early detection and improving patient outcomes.
- Strategic Expansion Plans: This authorization not only strengthens Biomerica's market position in the Middle East and North Africa but also provides opportunities for large-scale screening initiatives in underserved areas, further advancing global preventive healthcare trends.
See More
